Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 575 | 118 | 446 |
| Samples | 521 | 97 | 415 |
| Peptides | 433 | 76 | 357 |
Function
TOP2A · DNA topoisomerase II alpha
This gene encodes a DNA topoisomerase, an enzyme that controls and alters the topologic states of DNA during transcription. This nuclear enzyme is involved in processes such as chromosome condensation, chromatid separation, and the relief of torsional stress that occurs during DNA transcription and replication. It catalyzes the transient breaking and rejoining of two strands of duplex DNA which allows the strands to pass through one another, thus altering the topology of DNA. Two forms of this enzyme exist as likely products of a gene duplication event. The gene encoding this form, alpha, is localized to chromosome 17 and the beta gene is localized to chromosome 3. The gene encoding this enzyme functions as the target for several anticancer agents and a variety of mutations in this gene have been associated with the development of drug resistance. Reduced activity of this enzyme may also play a role in ataxia-telangiectasia. [provided by RefSeq, Jul 2010].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000423485 | P11388 | 575 | 433 |
Gene Properties
Recurrent Mutations
All 433 amino-acid changes on canonical ENST00000423485 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in TOP2A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in TOP2A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 11/40 28% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Endometrial Carcinoma | 3/42 7% | 22/612 4% |
| Melanoma | 6/210 3% | 58/1899 3% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Ovarian Carcinoma | 4/109 4% | 17/998 2% |
| Burkitts Lymphoma | 1/32 3% | 3/196 2% |
| Other Solid Cancers | 1/94 1% | 25/1515 2% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 21/1390 2% |
| Bladder Carcinoma | 0/58 0% | 15/956 2% |
| Colorectal Carcinoma | 15/143 10% | 33/3239 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 10/752 1% |
| Biliary Tract Carcinoma | 3/54 6% | 10/950 1% |
| Hepatocellular Carcinoma | 0/46 0% | 27/2210 1% |
| Plasma Cell Myeloma | 3/44 7% | 1/305 0% |
| Gastric Carcinoma | 3/74 4% | 18/1809 1% |
| Neuroendocrine Tumour | 4/154 3% | 4/577 1% |
| Other Sarcomas | 2/69 3% | 6/699 1% |
| Prostate Carcinoma | 1/13 8% | 21/2105 1% |
| Germ Cell Tumour | 1/25 4% | 1/169 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 16/1592 1% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 8/810 1% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Kidney Carcinoma | 1/85 1% | 14/1862 1% |
| Pancreatic Carcinoma | 4/89 4% | 9/1611 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Hodgkins Lymphoma | 1/16 6% | 0/122 0% |
| Glioma | 2/52 4% | 13/2127 1% |
| Head and Neck Carcinoma | 0/85 0% | 11/1574 1% |
Mutation Distribution
Where TOP2A is mutated · all tissues, split by cell line vs tissue
How many mutations in TOP2A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 575 mutations in TOP2A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|